MISSIONPHARMA A/S: Financial statements 2021
CVR: 26902398
Source: annual report 2021, Danish Business Authority
01/04/2020 – 31/03/2021
MISSIONPHARMA A/S (CVR 26902398) has filed annual accounts for 2021. In 2021, the company reported revenue of DKK 731,472,000 and a net result of DKK 83,607,000 compared with DKK 22,237,000 the year before. That is a decrease of 5.9% compared with the year before. The profit margin was 11.4%. Equity in the 2021 report amounted to DKK 332,425,000. The solvency ratio was 77.8%. The company had 58 employees in the financial year.
- Revenue
- DKK 731,472,000
- Gross Profit
- DKK 171,926,000
- Profit/Loss
- DKK 83,607,000
- Equity
- DKK 332,425,000
- Total Assets
- DKK 427,212,000
- Employees
- 58
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | 731.5M | 171.9M | 83.6M | 332.4M | 58 |
| 2020 | 777M | 81.5M | 22.2M | 263.2M | 62 |
| 2019 | 117.2M | 17M | 6M | 40.6M | 62 |
| 2017 | 703.5M | 137.1M | 76.2M | 284M | 60 |
| 2016 | 762.7M | 142.6M | 78M | 209M | 57 |
Official annual report
Find more companies like MISSIONPHARMA A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
As of November 30, 2021, Alexandre Pierre Jean Vialatte is registered as director of MISSIONPHARMA A/S.
As of November 30, 2021, Poul Lindof has stepped down as økonomidirektør of MISSIONPHARMA A/S.
About MISSIONPHARMA A/S
MISSIONPHARMA A/S is a Danish company of the type Aktieselskab based in Lynge, founded in 2002. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Jean-Marc Pierre René Leccia and Edouard Marc Marie Favreau. The board consists of Eric Pierre Jean Muris (chair), Kim Erik Ginnerup, Ilona Maureen Fischer and Jean-Marc Pierre René Leccia. The company is owned by CFAO HEALTHCARE SA. The company has 60 employees (2026). In 2026, the company reported revenue of DKK 934,465,000 and a net result of DKK 120,205,000 compared with DKK 73,402,000 the year before. Equity in the 2026 report amounted to DKK 317,751,000.